Patents by Inventor Stephen Qitu Wu
Stephen Qitu Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220241393Abstract: The present invention relates to modified, live Porcine Reproductive and Respiratory Syndrome viruses. Viruses were genetically analyzed and selected based on phylogenetic grouping for modification by repeated passage in tissue culture. The modified, live viruses were assessed for the ability to provide protective immunity to heterologous viruses. The modified, live viruses are useful in vaccines, particularly in vaccines which can treat infection of swine by multiple heterologous viruses.Type: ApplicationFiled: September 27, 2019Publication date: August 4, 2022Inventors: Stephen Qitu WU, Cinta Prieto SUAREZ, Geoffrey Gregory LABARQUE
-
Patent number: 10300126Abstract: The present invention relates to modified, live Porcine Reproductive and Respiratory Syndrome viruses. Viruses were genetically analyzed and selected based on phylogenetic grouping for modification by repeated passage in tissue culture. The modified, live viruses were assessed for the ability to provide protective immunity to heterologous viruses. The modified, live viruses are useful in vaccines, particularly in vaccines which can treat infection of swine by multiple heterologous viruses.Type: GrantFiled: October 4, 2018Date of Patent: May 28, 2019Assignee: Elanco US Inc.Inventors: Ying Fang, Stephen Qitu Wu
-
Publication number: 20190022208Abstract: The present invention relates to modified, live Porcine Reproductive and Respiratory Syndrome viruses. Viruses were genetically analyzed and selected based on phylogenetic grouping for modification by repeated passage in tissue culture. The modified, live viruses were assessed for the ability to provide protective immunity to heterologous viruses. The modified, live viruses are useful in vaccines, particularly in vaccines which can treat infection of swine by multiple heterologous viruses.Type: ApplicationFiled: October 4, 2018Publication date: January 24, 2019Inventors: Ying Fang, Stephen Qitu Wu
-
Patent number: 10155035Abstract: The present invention relates to modified, live Porcine Reproductive and Respiratory Syndrome viruses. Viruses were genetically analyzed and selected based on phylogenetic grouping for modification by repeated passage in tissue culture. The modified, live viruses were assessed for the ability to provide protective immunity to heterologous viruses. The modified, live viruses are useful in vaccines, particularly in vaccines which can treat infection of swine by multiple heterologous viruses.Type: GrantFiled: February 10, 2017Date of Patent: December 18, 2018Assignee: Elanco US Inc.Inventors: Ying Fang, Stephen Qitu Wu
-
Publication number: 20170239343Abstract: The present invention relates to modified, live Porcine Reproductive and Respiratory Syndrome viruses. Viruses were genetically analyzed and selected based on phylogenetic grouping for modification by repeated passage in tissue culture. The modified, live viruses were assessed for the ability to provide protective immunity to heterologous viruses. The modified, live viruses are useful in vaccines, particularly in vaccines which can treat infection of swine by multiple heterologous viruses.Type: ApplicationFiled: February 10, 2017Publication date: August 24, 2017Inventors: Ying Fang, Stephen Qitu Wu
-
Patent number: 8795681Abstract: The present invention relates to recombinant raccoon poxvirus vectors that express the rabies virus glycoprotein gene at the hemagglutinin (ha) locus of the poxvirus genome or express the glycoprotein gene of the same or different rabies strains at the thymidine kinase (tk) and the hemagglutinin (ha) loci of the poxvirus genome, and their use as adjuvant-free vaccines. The raccoon poxvirus vector comprises the nucleic acid molecules encoding the glycoprotein of a Challenge Virus Standard rabies strain inserted and expressed at the tk locus of the poxvirus genome and of a Pasteur-Paris rabies strain inserted and expressed at the ha locus of the poxvirus genome. The vaccine may optionally contain a mixture of additional feline and canine antigens for immunization of animals. Also disclosed are methods for inducing an immune response to rabies in a mammal by administering to the mammal an effective immunizing amount of the vaccine of the invention.Type: GrantFiled: May 28, 2008Date of Patent: August 5, 2014Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Stephen Qitu Wu, Michael A. Gill, Hsien-Jue Chu
-
Publication number: 20110305725Abstract: The present invention relates to the isolation and identification of two new strains of type 2B porcine circovirus. These two new strains of porcine circovirus may be used for the preparation of vaccine or immunogenic compositions for immunizing pigs against postweaning multisystemic wasting syndrome (PMWS). Accordingly, the invention provides methods for eliciting a protective immune response against a pathogenic porcine circovirus by administering to a pig an immunogenically effective amount of a type 2B porcine circovirus vaccine or immunogenic composition comprising at least one of the porcine circoviruses having a nucleic acid sequence as set forth in SEQ ID NOs: 1 or 2, or at least one protein from at least one of the two new type 2B strains of porcine circovirus as described herein. The invention further relates to protection of a pig from any one or more of the symptoms or sequelae associated with PMWS.Type: ApplicationFiled: March 9, 2011Publication date: December 15, 2011Applicant: WYETH LLCInventor: STEPHEN QITU WU
-
Publication number: 20090162398Abstract: The present invention relates to the isolation and identification of two new strains of type 2B porcine circovirus. These two new strains of porcine circovirus may be used for the preparation of vaccine or immunogenic compositions for immunizing pigs against postweaning multisystemic wasting syndrome (PMWS). Accordingly, the invention provides methods for eliciting a protective immune response against a pathogenic porcine circovirus by administering to a pig an immunogenically effective amount of a type 2B porcine circovirus vaccine or immunogenic composition comprising at least one of the porcine circoviruses having a nucleic acid sequence as set forth in SEQ ID NOs: 1 or 2, or at least one protein from at least one of the two new type 2B strains of porcine circovirus as described herein. The invention further relates to protection of a pig from any one or more of the symptoms or sequelae associated with PMWS.Type: ApplicationFiled: December 18, 2008Publication date: June 25, 2009Applicant: WyethInventor: Stephen Qitu Wu
-
Publication number: 20090017064Abstract: The present invention relates to compositions and methods of eliciting a cross-protective immune response against a pathogenic porcine circovirus by administering to a pig an immunogenically effective amount of a type 1-type 2 chimeric porcine circovirus vaccine. The chimeric vaccine utilized for cross-protection may be administered as a single dose or as multiple doses. The invention further relates to protection of the pig from any one or more of the symptoms or sequelae associated with postweaning multisystemic wasting syndrome (PMWS). Moreover, the administering of the chimeric vaccine also results in reduction in the higher than average mortality associated with the high mortality type 2B strains of porcine circovirus.Type: ApplicationFiled: July 9, 2008Publication date: January 15, 2009Applicant: WyethInventors: Stephen Qitu Wu, Michael A. Gill, Hsien-Jue Chu
-
Publication number: 20090010963Abstract: The present invention relates to recombinant raccoon poxvirus vectors that express the rabies virus glycoprotein gene at the hemagglutinin (ha) locus of the poxvirus genome or express the glycoprotein gene of the same or different rabies strains at the thymidine kinase (tk) and the hemagglutinin (ha) loci of the poxvirus genome, and their use as adjuvant-free vaccines. The raccoon poxvirus vector comprises the nucleic acid molecules encoding the glycoprotein of a Challenge Virus Standard rabies strain inserted and expressed at the tk locus of the poxvirus genome and of a Pasteur-Paris rabies strain inserted and expressed at the ha locus of the poxvirus genome. The vaccine may optionally contain a mixture of additional feline and canine antigens for immunization of animals. Also disclosed are methods for inducing an immune response to rabies in a mammal by administering to the mammal an effective immunizing amount of the vaccine of the invention.Type: ApplicationFiled: May 28, 2008Publication date: January 8, 2009Applicant: WyethInventors: Stephen Qitu Wu, Michael A. Gill, Hsien-Jue Chu
-
Publication number: 20080299141Abstract: The present invention relates to a new recombinant raccoon poxvirus vector vaccine in which the vector expresses one or more antigenic proteins encoded by multiple open reading frames, preferably the ORF5, ORF6 and/or ORF3/ORF4/ORF7, of one or more porcine reproductive and respiratory syndrome virus strains alone or in combination with an open reading frame of porcine circovirus type 2 (PCV-2), preferably ORF2, at the hemagglutinin (ha) and/or thymidine kinase (tk) loci.Type: ApplicationFiled: May 28, 2008Publication date: December 4, 2008Applicant: WyethInventors: Stephen Qitu Wu, Michael A. Gill, Hsien-Jue Chu
-
Publication number: 20080299149Abstract: The present invention relates to new recombinant raccoon poxvirus vectors comprising two or more exogenous nucleic acid molecules, each encoding at least one feline protein, wherein at least two of the nucleic acid molecules are inserted into the hemagglutinin (ha) locus or the thymidine kinase (tk) locus, or at least one of the nucleic acid molecules is inserted into each of the hemagglutinin and thymidine kinase loci. Described herein are monovalent and polyvalent recombinant feline vaccines that encompass an immunologically effective amount of the recombinant raccoon poxvirus vectors and, optionally, a suitable carrier or diluent. The vaccine of this invention optionally includes additional feline antigens to provide broad spectrum protection to cats against a variety of feline pathogens. The invention further concerns the method for inducing a protective immune response to the feline pathogens in a cat by administering the recombinant vaccines.Type: ApplicationFiled: May 28, 2008Publication date: December 4, 2008Applicant: WyethInventors: Stephen Qitu Wu, Michael A. Gill, Hsien-Jue Chu